Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

These studies have shown that PPF 300 mg t.i.d. is safe and well tolerated when taken on an empty stomach 1 h before meals. In a randomized, double-blind phase II study involving 190 elderly subjects with clinically and psychometrically documented mild to moderate dementia, 12 weeks of PPF therapy produced significantly greater improvements than placebo in Gottfries-Bråne-Steen (GBS) scores, Mini-Mental State Examination (MMSE) scores, and Clinical Global Impression (CGI) ratings. A subsequent phase II study using positron emission tomography (PET) revealed that cortical glucose metabolism improved significantly in patients with vascular dementia after 12 weeks of PPF treatment but deteriorated significantly with placebo. A third phase II study, which enrolled patients with Alzheimer-type dementia, demonstrated that PPF significantly enhanced functional reserve, as reflected by increases in regional cerebral glucose metabolism after stimulation with a verbal memory task. In contrast, patients randomized to placebo exhibited a significant decline in functional activation and significant worsening in their MMSE scores over the course of this 12-week study. Phase I trial results suggest that significant food interactions occur with PPF, indicating that the drug should be taken on an empty stomach 1 h before meals. Phase II trial results indicate that PPF yields clinically measurable improvements in the symptoms of dementia and prevents loss of stimulation-related increases in glucose metabolism over a treatment period of 3 months. Whether these results indicate that PPF can slow the progression of dementia can be determined only by long-term trials specifically designed to determine the drug's effect on disease progression.

What this study adds

Evidence grade: High

This is a narrative review. In phase II trials, propentofylline (PPF) 300 mg three times daily improved cognitive scores and brain glucose metabolism compared with placebo in people with mild to moderate vascular or Alzheimer-type dementia. These were early-phase studies, and the text notes PPF should be taken on an empty stomach one hour before meals because of food interactions.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mielke, R., Möller, H. J., Erkinjuntti, T., Rosenkranz, B., Rother, M., & Kittner, B. (1998). Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer disease and associated disorders.

Vancouver

Mielke R, Möller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer disease and associated disorders. 1998. PMID: 9769027.

BibTeX

@article{mielke1998-9769027,
  author  = {Mielke, R. and Möller, H. J. and Erkinjuntti, T. and Rosenkranz, B. and Rother, M. and Kittner, B.},
  title   = {{Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials}},
  journal = {Alzheimer disease and associated disorders},
  year    = {1998},
  pmid    = {9769027}
}

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In phase II trials, propentofylline (PPF) 300 mg three times daily improved cognitive scores and brain glucose metabolism compared with placebo in people with mild to moderate vascular or Alzheimer-type dementia. These were early-phase studies, and the text notes PPF should be taken on an empty stomach one hour before meals because of food interactions.

Study details

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 1 of 2; Times cited 4 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 34 of the 92 points it could be judged on, which is 37 of 100. Total 37 of 100.34 of the 92 points we could judge = 37 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 34 of the 92 points we could judge it on, which is 37 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1998 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 4 / 7 Cited 45 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.5 citations a year over 30 year(s) since 1998
Impact for its field and year 2 / 6 Cited 3.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author B Kittner holds only 2 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 University of Cologne: institution h-index 879 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 9769027)
Free to read 0 / 2 Behind a paywall — scores zero
Points 34 / 92 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 34 of the 92 points we could judge it on is 37 out of 100.
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →